Peptides Offer Strategies for Novel Immunosuppressants and Anti-Herpes Agents
Tech ID: 96-02
Summary - National Jewish Health researchers have identified peptide sequences from RAG proteins and Herpes virus proteins that correspond to a DDE catalytic site in retroviral integrases. The DDE site in retroviral integrases regulates DNA cleavage. Blockage of the corresponding site in RAG proteins, using the peptides or their homologues, offers a novel approach to regulation of immune responses by targeting V(D)J recombination in immune cells. Blockage of the site in Herpes viruses could inhibit replication of the virus by interfering with the function of viral DNA Binding Proteins.
- Treatment of autoimmune diseases
- Prevention of immune system rejection of foreign graft tissue
- Treatment of Herpes virus infection
Advantages of Invention - Drugs targeting V(D)J recombination may avoid broad immunosuppressive effects of currently available medicines for autoimmune conditions or graft rejection. Drugs targeting genetic recombination of Herpes viruses may enhance the effectiveness of anti-viral therapy based on nucleoside analogues, while avoiding the side effects of nucleoside analogues or their tendency to induce resistance.
State of Development - Peptides containing recombinogenic motifs have been identified.
Patent - US Patents #5,959,074 and #6,187,584.
Inventors - Erwin Gelfand, MD and David Dreyfus, MD, PhD
Licensing Status - This technology is available for licensing.
For Further Information, Contact:
Emmanuel Hilaire, PhD
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206